Today, Bluebird Bio Inc. (BLUE) Receives Buy Rating from Janney Montgomery Scott

Today, Bluebird Bio Inc. (BLUE) Receives Buy Rating from Janney Montgomery Scott
Bluebird Bio Inc. (NASDAQ:BLUE)‘s stock had its “buy” rating reiterated by research analysts at Janney Montgomery Scott in a note issued to investors on Thursday.

A number of other equities analysts have also commented on the stock. Jefferies Group reiterated a “buy” rating and issued a $80.00 price objective on shares of Bluebird Bio in a report on Thursday. Wedbush reiterated an “outperform” rating and issued a $95.00 price objective on shares of Bluebird Bio in a report on Wednesday. BMO Capital Markets assumed coverage on shares of Bluebird Bio in a report on Thursday, November 10th. They issued a “market perform” rating and a $61.00 price objective on the stock. BTIG Research reiterated a “buy” rating and issued a $83.00 price objective on shares of Bluebird Bio in a report on Monday, November 7th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $80.00 price objective on shares of Bluebird Bio in a report on Monday, November 7th. One research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $82.82.

Shares of Bluebird Bio (NASDAQ:BLUE) traded up 2.32% during trading on Thursday, hitting $63.95. The company’s stock had a trading volume of 505,529 shares. The company’s market cap is $2.39 billion. The firm’s 50 day moving average price is $56.23 and its 200-day moving average price is $52.68. Bluebird Bio has a 52 week low of $35.37 and a 52 week high of $94.61.

Bluebird Bio (NASDAQ:BLUE) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported ($2.07) EPS for the quarter, missing analysts’ consensus estimates of ($1.59) by $0.48. Bluebird Bio had a negative return on equity of 30.79% and a negative net margin of 3,941.72%. The firm earned $1.55 million during the quarter, compared to analyst estimates of $1.82 million. During the same quarter in the prior year, the firm earned ($1.18) EPS. The business’s quarterly revenue was up 17.4% compared to the same quarter last year. On average, analysts predict that Bluebird Bio will post ($7.05) earnings per share for the current year.

In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the company’s stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $67.00, for a total value of $27,872.00. Following the completion of the transaction, the insider now owns 5,891 shares in the company, valued at approximately $394,697. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 3.50% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Advisors LLC boosted its position in Bluebird Bio by 0.8% in the second quarter. BlackRock Advisors LLC now owns 17,403 shares of the company’s stock valued at $753,000 after buying an additional 134 shares during the period. Canada Pension Plan Investment Board boosted its position in Bluebird Bio by 3.1% in the second quarter. Canada Pension Plan Investment Board now owns 19,800 shares of the company’s stock valued at $857,000 after buying an additional 600 shares during the period. California State Teachers Retirement System boosted its position in Bluebird Bio by 1.0% in the third quarter. California State Teachers Retirement System now owns 78,487 shares of the company’s stock valued at $5,320,000 after buying an additional 800 shares during the period. Teacher Retirement System of Texas boosted its position in Bluebird Bio by 25.3% in the second quarter. Teacher Retirement System of Texas now owns 5,114 shares of the company’s stock valued at $221,000 after buying an additional 1,034 shares during the period. Finally, Principal Financial Group Inc. boosted its position in Bluebird Bio by 5.7% in the third quarter. Principal Financial Group Inc. now owns 21,270 shares of the company’s stock valued at $1,442,000 after buying an additional 1,154 shares during the period.

Bluebird Bio Company Profile

Related posts

Leave a Comment